CinCor Pharma, Inc. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic.
Latest period: Q3 2022.
-
Location
-
Waltham, MA
-
Fiscal year end
-
31 December
-
Latest financial report
-
03 Nov 2022
Quick Takeaways
- CinCor Pharma, Inc. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q3 2022.
- Headline metric: Return On Equity -37%.
What Changed
- Return On Equity YoY change: <span class="text-red-600">-285%</span>.
- Most recent SEC facts end date: 03 Nov 2022.
Why This Matters
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Official SEC Source
Based on latest 10-Q/10-K
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original Filing
Latest SEC snapshot (2022-11-03) highlights Return On Equity -37.2%, Return On Assets -16.6%, and Current Ratio 51.96x.
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
1.0/100
Weak
Confidence low
Return On Equity
-37%
Metric score 0.0/100
Return On Assets
-17%
Metric score 0.0/100
Financial Health
- Current Ratio
- 51.96x
Strengths
No strong signals yet.
Watchpoints
Return On Equity, Return On Assets, and Current Ratio
Key metrics snapshot
Return On Equity
-37%
YoY: -285%
Industry median:
-43%
(n=675)
View history
Return On Assets
-17%
YoY:
Industry median:
-47%
(n=673)
View history
Current Ratio
51.96x
YoY:
Industry median:
3.39x
(n=667)
View history
NetIncomeLoss YoY
-132%
YoY:
Industry median:
-0.93%
(n=641)
View history
Profitability
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
Return On Equity
|
-37%
|
-285%
|
-43%
(n=675)
|
Q3 2022
|
Q3 2022
|
%
|
|
Return On Assets
|
-17%
|
|
-47%
(n=673)
|
Q3 2022
|
Q3 2022
|
%
|
Financial Health
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
Current Ratio
|
51.96x
|
|
3.39x
(n=667)
|
Q3 2022
|
Q3 2022
|
x
|
Growth
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
NetIncomeLoss YoY
|
-132%
|
|
-0.93%
(n=641)
|
Q3 2022
|
Q3 2022
|
%
|
Share Metrics
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
Entity Common Stock, Shares Outstanding
|
43,764,323
|
|
Q3 2022
|
Q3 2022
|
shares
|
|
Common Stock, Shares, Outstanding
|
43,764,323
|
|
Q3 2022
|
Q3 2022
|
shares
|
|
Common Stock, Value, Issued
|
$438
|
|
Q3 2022
|
Q3 2022
|
USD
|
|
Weighted Average Number of Shares Outstanding, Basic
|
40,806,123
|
+2246%
|
Q3 2022
|
Q3 2022
|
shares
|
|
Weighted Average Number of Shares Outstanding, Diluted
|
40,806,123
|
+2246%
|
Q3 2022
|
Q3 2022
|
shares
|
Additional Metrics
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
Research and Development Expense
|
$53,939,275
|
+281%
|
Q3 2022
|
Q3 2022
|
USD
|
|
General and Administrative Expense
|
$28,595,335
|
+49%
|
Q3 2022
|
Q3 2022
|
USD
|
|
Operating Income (Loss)
|
$82,534,610
|
-189%
|
Q3 2022
|
Q3 2022
|
USD
|
|
Nonoperating Income (Expense)
|
$8,530,751
|
-195%
|
Q3 2022
|
Q3 2022
|
USD
|
|
Earnings Per Share, Basic
|
-0.51
|
+90%
|
Q3 2022
|
Q3 2022
|
USD/shares
|
|
Earnings Per Share, Diluted
|
-0.51
|
+90%
|
Q3 2022
|
Q3 2022
|
USD/shares
|
|
Cash and Cash Equivalents, at Carrying Value
|
$292,556,851
|
|
Q3 2022
|
Q3 2022
|
USD
|
|
Assets, Current
|
$529,019,366
|
|
Q3 2022
|
Q3 2022
|
USD
|
|
Property, Plant and Equipment, Net
|
$99,722
|
|
Q3 2022
|
Q3 2022
|
USD
|
|
Assets
|
$529,119,088
|
|
Q3 2022
|
Q3 2022
|
USD
|
|
Accounts Payable, Current
|
$2,588,400
|
|
Q3 2022
|
Q3 2022
|
USD
|
|
Employee-related Liabilities, Current
|
$0
|
|
Q3 2022
|
Q3 2022
|
USD
|
|
Accrued Liabilities, Current
|
$2,481,232
|
|
Q3 2022
|
Q3 2022
|
USD
|
|
Liabilities, Current
|
$10,181,519
|
|
Q3 2022
|
Q3 2022
|
USD
|
|
Accumulated Other Comprehensive Income (Loss), Net of Tax
|
$883,417
|
|
Q3 2022
|
Q3 2022
|
USD
|
|
Retained Earnings (Accumulated Deficit)
|
$136,452,934
|
|
Q3 2022
|
Q3 2022
|
USD
|
|
Stockholders' Equity Attributable to Parent
|
$518,937,569
|
|
Q3 2022
|
Q3 2022
|
USD
|
|
Liabilities and Equity
|
$529,119,088
|
|
Q3 2022
|
Q3 2022
|
USD
|
|
Common Stock, Shares Authorized
|
95,000,000
|
|
Q3 2022
|
Q3 2022
|
shares
|
|
Common Stock, Par or Stated Value Per Share
|
0
|
|
Q3 2022
|
Q3 2022
|
USD/shares
|
|
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
|
$292,556,851
|
+106%
|
Q3 2022
|
Q3 2022
|
USD
|
|
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
|
$21,149,210
|
-134%
|
Q3 2022
|
Q3 2022
|
USD
|
|
Additional Paid in Capital
|
$656,273,482
|
|
Q3 2022
|
Q3 2022
|
USD
|
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric |
Weight |
V1 threshold |
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY
Explore related SEC datasets